Research paper
Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers

https://doi.org/10.1016/1380-2933(95)00027-5Get rights and content

Abstract

Background: Genetic engineering can produce novel antibody fragments with improved properties for applications such as tumor targeting in vivo. Objectives: To produce stable monomeric (27 kDa) and dimeric (55 kDa) forms of a single-chain Fv (scFv) from the anti-carcinoembryonic antigen (anti-CEA) antibody T84.66, and assess the targeting and biodistribution properties in an animal model. Study design: ScFv were constructed with either a 28 or 14 amino acid connecting peptide and expressed by secretion from E. coli. Following affinity purification, proteins were characterized by gel electrophoresis and mass spectrometry. Binding properties were assessed by size exclusion HPLC after incubation with antigen, and affinities determined by surface plasmon resonance. The shorter linker favored formation of dimers (and higher multimers) which showed unusual stability. ScFv were radiolabeled with 125I for tumor targeting and biodistribution studies of monomeric or dimeric forms were conducted in athymic mice bearing LS 174T human colorectal carcinoma xenografts. Results: 125I-scFv monomers and dimers targeted exhibited rapid clearance kinetics in tumor-bearing mice. Nevertheless, the anti-CEA scFvs targeted very well to xenografts, leading to high tumor: normal organ ratios (greater than 20:1 at 24 h) for both forms. Tumor localization of the non-covalent dimers was much higher than monomers, reaching 10–15% injected dose per gram at 1 h. Conclusion: Non-covalent dimers of scFv (also known as diabodies) are stable, easy to produce and show excellent targeting as compared to monomeric scFv, probably due to increased mass and valency.

References (48)

  • W.D. Mallender et al.

    J. of Biol. Chem.

    (1994)
  • D.P. McGregor et al.

    Mol. Immunol.

    (1994)
  • N.Z. Essig et al.

    J. Mol. Biol.

    (1993)
  • J.M. Esteban et al.

    Hum. Path.

    (1993)
  • R.M. Horton et al.

    Gene

    (1989)
  • J. Calaycay et al.

    Anal. Biochem.

    (1991)
  • J.E. Coligan et al.

    Immunochemistry

    (1972)
  • P.J. Fraker et al.

    Biochem. Biophys. Res. Commun.

    (1978)
  • D.Z. D'Argenio et al.

    Comput. Prog. Biomed.

    (1979)
  • R. Abraham et al.

    J. Immunol. Methods

    (1995)
  • T.A. Waldmann

    Science

    (1991)
  • L.M. Lamki et al.

    Radiology

    (1990)
  • J.D. Beatty et al.

    Canc. Res.

    (1986)
  • R.M. Corbisiero et al.

    Canc. Res.

    (1991)
  • C.R. Divgi et al.

    J. Nucl. Med.

    (1993)
  • P.J. Moldofsky et al.

    Radiology

    (1983)
  • S.M. Larson et al.

    J. Clin. Invest.

    (1983)
  • B. Delaloye et al.

    J. Clin. Invest.

    (1986)
  • A.A. Epenetos et al.

    Lancet

    (1982)
  • F.L. Moffat et al.

    Cancer

    (1994)
  • P. Lind et al.

    Int. J. Cancer

    (1991)
  • F. Buchegger et al.

    J. Exp. Med.

    (1983)
  • F. Buchegger et al.

    J. Nucl. Med.

    (1990)
  • S.L. Morrison

    Ann. Rev. Immunol.

    (1992)
  • Cited by (194)

    • Association behavior and control of the quality of cancer therapeutic bispecific diabodies expressed in Escherichia coli

      2020, Biochemical Engineering Journal
      Citation Excerpt :

      These diabodies can be expressed in a conventional host such as Escherichia coli, while maintaining their binding ability and cytotoxicity to cancer cells [8–10]. Furthermore, the low molecular weight of diabodies allow for easy penetration of tumors that are immune to IgG [11], low immunogenicity [12], and application for the design of orally administered therapeutics [13]. Conversely, diabodies were reported to have disadvantages, in that they generally contain both an inactive monomer or homodimer form as well as an active heterodimer, in solution [14–17].

    • Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy

      2019, Advanced Drug Delivery Reviews
      Citation Excerpt :

      These bivalent products retain the avidity and long tumor residence time of the parental full IgG counterpart. Good in vivo selectivity profiles (i.e., tumor: organ ratios) have been reported for numerous diabody-based products [27,29]. The spatial arrangement of the antibody and cytokine moieties can have a profound influence on the in vivo performance of the corresponding product.

    • Pharmacokinetics of protein and peptide conjugates

      2019, Drug Metabolism and Pharmacokinetics
    • Photodynamic activity of thiophene-derived lysosome-specific dyes

      2016, Journal of Photochemistry and Photobiology B: Biology
    View all citing articles on Scopus
    View full text